Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

Mueller,Sarah-Kristin; Altvater,Bianca; Chen,Christiane; Kailayangiri,Sareetha; Ahlmann,Martina; Dirksen,Uta; Juergens,Heribert; Rossig,Claudia

doi:10.3892/or.2013.2350

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

Authors:
- Sarah-Kristin Mueller
- Bianca Altvater
- Christiane Chen
- Sareetha Kailayangiri
- Martina Ahlmann
- Uta Dirksen
- Heribert Juergens
- Claudia Rossig
View Affiliations

Affiliations: Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
Published online on: March 19, 2013 https://doi.org/10.3892/or.2013.2350
Pages: 2348-2354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Disseminated Ewing sarcoma remains a fatal disease despite advanced multimodal treatment regimens. Immunotherapies as well as novel drugs and biologicals are currently being explored to eliminate minimal residual disease after conventional therapy thereby rescuing patients at a high risk for relapse. Insights into the interactions between novel therapies provide the basis for the development of effective combination strategies. We investigated the effects of the aminobisphosphonate zoledronic acid (ZA) on the in vitro expansion of human natural killer (NK) cells and their cytolytic activity against Ewing sarcoma cells. ZA significantly impaired the in vitro expansion of activated NK cells from both healthy donors and Ewing sarcoma patients in a dose-dependent manner. Expression of differentiation markers and activating receptors was unaffected by the drug. Activated NK cells from both healthy donors and patients had potent degranulation responses to Ewing sarcoma cells. In the presence of ZA at concentrations reflecting pharmaceutical serum levels, the in vitro antitumor activity of NK cells from Ewing sarcoma patients was significantly impaired. We conclude that ZA can impede in vitro NK cell expansion and cytolytic NK cell responses to Ewing sarcoma. These observations raise caution against the combination of adoptive NK cell transfer with ZA maintenance therapy in Ewing sarcoma. Future studies aim to identify potentiating interactions of novel drugs with cellular therapies.

View Figures

View References

1	Potratz J, Dirksen U, Jurgens H and Craft A: Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol. 29:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
2	Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 22:488–493. 1996. View Article : Google Scholar : PubMed/NCBI
3	Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D’Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
4	Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, et al: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing’s sarcoma patients. Cancer Res. 70:7610–7619. 2010.PubMed/NCBI
5	Zhou Z, Guan H, Duan X and Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 104:1713–1720. 2005. View Article : Google Scholar : PubMed/NCBI
6	Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH and Child JA: Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 119:5374–5383. 2012. View Article : Google Scholar : PubMed/NCBI
7	Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini F: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 37:74–86. 2005. View Article : Google Scholar : PubMed/NCBI
8	Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, et al: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11:421–428. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I and Karamanos NK: The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 125:1705–1709. 2009. View Article : Google Scholar : PubMed/NCBI
10	Siddiqui T, Marsh RW, Allegra C, Whittaker D, Scarborough M, Gibbs P, Zlotecki R, Reith JD and Drane W: Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid. Clin Adv Hematol Oncol. 8:499–504. 2010.PubMed/NCBI
11	Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A and June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra732011. View Article : Google Scholar : PubMed/NCBI
12	Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 16:3901–3909. 2010. View Article : Google Scholar : PubMed/NCBI
13	Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N and Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 58:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
14	Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H and Wargo JA: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70:5213–5219. 2010. View Article : Google Scholar : PubMed/NCBI
15	Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
16	Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A and Odum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65:11136–11145. 2005. View Article : Google Scholar
17	Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP, Egeler RM, Hogendoorn PC and Lankester AC: Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2:82012. View Article : Google Scholar : PubMed/NCBI
18	Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP and Hayball JD: Dasatinib inhibits recombinant viral antigen-specific murine CD4⁺ and CD8⁺ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 37:256–265. 2009. View Article : Google Scholar : PubMed/NCBI
19	Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI and Zwirner NW: Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol. 91:321–331. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, et al: Effector gamma delta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 19:664–670. 2005.PubMed/NCBI
21	Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg K, Werth D, Grünebach F and Brossart P: Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia. 21:732–738. 2007.PubMed/NCBI
22	Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I and Thiebaud D: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res. 15:147–154. 2000. View Article : Google Scholar : PubMed/NCBI
23	Liote F, Boval-Boizard B, Fritz P and Kuntz D: Lymphocyte subsets in pamidronate-induced lymphopenia. Br J Rheumatol. 34:993–995. 1995. View Article : Google Scholar
24	Nussbaumer O, Gruenbacher G, Gander H and Thurnher M: DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Blood. 118:2743–2751. 2011.PubMed/NCBI
25	Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, et al: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 49:40–51. 2010.PubMed/NCBI
26	Imai C, Iwamoto S and Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 106:376–383. 2005. View Article : Google Scholar : PubMed/NCBI
27	Alter G, Malenfant JM and Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 294:15–22. 2004. View Article : Google Scholar : PubMed/NCBI
28	Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, et al: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 42:1228–1236. 2002. View Article : Google Scholar : PubMed/NCBI
29	Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF and Lanier LL: CD57 defines a functionally distinct population of mature NK cells in the human CD56^dimCD16⁺ NK-cell subset. Blood. 116:3865–3874. 2010. View Article : Google Scholar : PubMed/NCBI
30	Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 102:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wang H, Sarikonda G, Puan KJ, Tanaka Y, Feng J, Giner JL, Cao R, Monkkonen J, Oldfield E and Morita CT: Indirect Stimulation of Human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol. 187:5099–5113. 2011.
32	Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens A and Kuball J: Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood. 118:50–59. 2011.
33	Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE and Chapoval AI: Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 116:1726–1733. 2010.
34	Sarhan D, D’Arcy P, Wennerberg E, Liden M, Hu J, Winqvist O, Rolny C and Lundqvist A: Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-gamma. Eur J Immunol. Sep 19–2012.(Epub ahead of print).
35	Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69:4010–4017. 2009. View Article : Google Scholar
36	Dowell AC, Oldham KA, Bhatt RI, Lee SP and Searle PF: Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4–1BBL and IL-12. Cancer Immunol Immunother. 61:615–628. 2012.PubMed/NCBI
37	Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ, Schilham MW and Lankester AC: NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol. 45:3917–3925. 2008. View Article : Google Scholar : PubMed/NCBI